Status:
RECRUITING
Negative HPV Test Results on Infinity/GeneXpert® With the Presence of a Late Amplification Signal: What Does This Mean ? (PaPCR)
Lead Sponsor:
University Hospital, Brest
Conditions:
Cervical Cancers
Papillomavirus Infections
Eligibility:
FEMALE
Brief Summary
The aim of this retrospective, single-center, observational study is to improve the diagnosis and interpretation of cervical cancer by better detection of epithelial lesions in the case of a late HPV ...
Detailed Description
Cervical cancer is the fourth most common cancer in women worldwide, with 660,000 new cases and 350,000 related deaths by 2022. Papillomavirus (HPV) infection is the most common sexually transmitted i...
Eligibility Criteria
Inclusion
- Patients whose cervico-uterine swab was initially rendered negative by the GeneXpert® system when a late Ct signal (\>35) was present in the raw result.
Exclusion
- Patients with a positive cervico-uterine swab for Papillomavirus.
- Patients with a negative test with no amplification signal.
- Patients who have expressed opposition to inclusion in the study.
- Patients under legal protection (guardianship, curatorship, etc.).
Key Trial Info
Start Date :
March 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2025
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT06919627
Start Date
March 1 2025
End Date
August 31 2025
Last Update
April 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de BREST
Brest, Brittany Region, France, 29200